查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018055

流感疫苗市場：2026-2032年全球市場預測（依疫苗類型、年齡層、劑量、配方、分銷管道和最終用戶分類）

Influenza Vaccine Market by Vaccine Type, Age Group, Dosage, Presentation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，流感疫苗市值將達到 94.1 億美元，到 2026 年將成長至 102.8 億美元，複合年成長率為 9.65%，到 2032 年將達到 179.4 億美元。

主要市場統計數據
基準年 2025 94.1億美元
預計年份：2026年 102.8億美元
預測年份 2032 179.4億美元
複合年成長率 (%) 9.65%

策略性導論，概述了技術創新、供應鏈韌性和政策趨勢的融合如何影響流感疫苗的決策。

在技​​術創新、人口結構變化和供應鏈監管日益嚴格的推動下，流感疫苗領域正在迅速演變。隨著公共衛生計畫和私人企業重新評估其優先事項，決策者越來越需要更清晰地了解疫苗平台、劑型和通路如何與監管預期和支付方趨勢相契合。本導言將介紹構成後續分析基礎的關鍵主題：抗原設計和生產平台的創新、低溫運輸和製劑形式選擇方面的實際情況，以及應對影響供應狀況和成本結構的政策和貿易趨勢的戰略舉措。

平台多元化、管理方法創新和供應鏈現代化如何重塑流感疫苗接種的市場動態和相關人員策略？

流感疫苗領域正經歷一場變革，這場變革遠不止於產品更新，它涵蓋了生產架構、劑型以及相關人員的合作模式。平台多元化是這場變革的核心。雖然去活化疫苗的生產仍在不斷最佳化加工能力和產量，減毒活病毒疫苗和重組疫苗等方法因其能夠誘導更廣泛的免疫反應並縮短生產週期而備受關注。同時，業界也越來越關注能夠提高給藥便利性和減少廢棄物的管瓶。這包括採用不同材料的預填充式注射器和旨在適應靈活給藥策略的西林瓶。

評估 2025 年美國關稅變化對疫苗價值鏈籌資策略、製造本地化和供應鏈韌性的多方面影響。

美國2025年實施的關稅調整的累積影響波及整個流感疫苗生態系統，波及採購決策、投入成本和供應鏈設計。依賴跨境採購專用耗材、注射器組件以及填充和包裝材料的製造商面臨更高的接收成本和更長的採購週期。為因應這項挑戰，各廠商採取了一系列策略來降低戰術性政策變化帶來的波動風險，包括供應商多元化、重新談判長期合約以及在地採購關鍵零件。

以細分市場主導的策略洞察，揭示疫苗類型、年齡層、劑量、配方、分銷管道和最終用戶特徵如何相互作用，從而影響商業化和供應。

細分市場分析揭示了基於疫苗類型、年齡層、劑量、配方、分銷管道和最終用戶背景的不同機會領域和營運重點。就疫苗類型而言，去活化疫苗、減毒活病毒疫苗疫苗和重組疫苗在生產前置作業時間、低溫運輸敏感性和臨床指導方面存在顯著差異，進而影響採購週期和臨床培訓需求。就年齡層而言，成人、老年人和兒童群體需要個人化的傳播策略、劑量考量和推廣模式，以最佳化疫苗接種率並最大限度地減少不利事件的擔憂。

美洲、歐洲、中東和非洲以及亞太地區的區域戰略考量和營運差異決定了准入和部署策略。

區域趨勢對流感疫苗策略的製定和實施有顯著影響，美洲、歐洲、中東和非洲以及亞太地區的營運、監管和市場進入的考量各不相同。在美洲，採購模式和公共衛生計畫強調在都市區開展全國性的免疫宣傳活動，並輔以完善的低溫運輸基礎設施，同時農村地區的疫苗可及性和公平分配仍然是重點關注的問題。此外，在一些主要地區，私營部門的通路和直接供應合約是商業性模式的重要組成部分。

一個由企業策略和夥伴關係構成的生態系統，結合了平台創新、專業製造和整合供應解決方案，以確保競爭優勢。

流感疫苗生態系統中各企業之間的競爭格局，是現有平台優勢、創新夥伴關係以及輔助成分和供應技術專業化共同作用的結果。成熟的疫苗生產商正努力平衡傳統去活化疫苗平台的效率與對重組和新型抗原技術的投資，以期獲得更快的應對力和潛在的免疫抗原性優勢。同時，契約製造組織（CMO）和專業的灌裝包裝供應商正透過實現靈活的規模化生產和地理分散的生產模式，以及降低跨境貿易波動帶來的風險，提升其戰略重要性。

為加強供應韌性、最佳化產品形式策略以及協調採購和監管方法以加快疫苗獲取，提出切實可行的建議。

產業領導者應優先致力於增強韌性、加速供應鏈創新，並使商業模式與公共衛生目標保持一致。首先，他們應投資於供應商多元化和在地化，以降低依賴單一供應商和貿易政策波動所帶來的風險。這包括與契約製造製造商建立策略合作關係，並對區域填充和包裝能力進行有針對性的投資，以縮短前置作業時間並提高供應穩定性。其次，他們應精簡劑型組合，權衡預填充式注射器的操作優勢與管瓶瓶的成本和物流優勢，並根據最終用戶的能力、特定年齡層的需求和廢棄物管理情況做出選擇。

結合二手分析、專家訪談、供應鏈映射和情境測試的穩健混合調查方法，可得出切實可行的見解。

本研究整合了定性和定量方法，旨在產生既反映宏觀趨勢又反映實際情況的可操作性見解。研究方法首先進行全面的二手資料調查，涵蓋同儕審查文獻、監管出版刊物和公共衛生指南，從而建構對平台技術、劑型和政策框架的基礎性理解。隨後，透過與製造業企業領導者、供應鏈高階主管、臨床醫生和採購專家等專家進行結構化訪談，進行一手調查，以補充上述基礎，並收集經驗見解和實際操作中的限制因素。

總之，該報告強調，需要在創新、採購和分銷方面採取綜合和分階段的策略，以確保疫苗的永續取得。

總之，流感疫苗生態系統正處於轉折點，平台創新、配方選擇和供應鏈韌性將共同決定該計畫的成敗。相關人員必須權衡各種複雜的利弊：一方面要考慮先進重組疫苗和減毒活病毒疫苗技術的優勢，另一方面要考慮生產能力和分銷系統的實際限制；此外，還要考慮預填充式注射器方案的運作效率，以及管瓶方案的成本和廢棄物問題。關稅相關的政策變化凸顯了採購和區域生產策略多元化的重要性，進一步強化了合約和營運柔軟性的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：流感疫苗市場：依疫苗類型分類

  • 失活
  • 減毒活病毒疫苗
  • 重組

第9章：流感疫苗市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第10章：流感疫苗市場：依劑量分類

  • 多次給藥
  • 單一劑量

第11章：流感疫苗市場：以劑型分類

  • 預填充式注射器
    • 玻璃預充式預填充式注射器
    • 塑膠預填充式注射器
  • 管瓶
    • 多管瓶小瓶
    • 單劑量管瓶

第12章：流感疫苗市場：依通路分類

  • 直銷
  • 醫院藥房

第13章：流感疫苗市場：依最終用戶分類

  • 診所
    • 門診部
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院

第14章：流感疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：流感疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 流感疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國流感疫苗市場

第18章：中國流感疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca plc
  • Changchun BCH Bioengineering Co., Ltd.
  • China National Pharmaceutical Group Co., Ltd.
  • CSL Limited
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Private Limited
  • Sinovac Biotech Ltd.
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Product Code: MRR-032A67D913E1

The Influenza Vaccine Market was valued at USD 9.41 billion in 2025 and is projected to grow to USD 10.28 billion in 2026, with a CAGR of 9.65%, reaching USD 17.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.41 billion
Estimated Year [2026] USD 10.28 billion
Forecast Year [2032] USD 17.94 billion
CAGR (%) 9.65%

A strategic introduction framing the convergence of technological innovation, supply chain resilience, and policy dynamics shaping influenza vaccine decision-making

The influenza vaccine landscape is evolving at pace, driven by technological innovation, shifting demographics, and intensified supply chain scrutiny. As public health programs and commercial players recalibrate priorities, decision-makers increasingly demand clarity on how vaccine platforms, delivery formats, and distribution pathways intersect with regulatory expectations and payer dynamics. This introduction frames the central themes that will inform subsequent analysis: innovation in antigen design and manufacturing platforms, the operational realities of cold chain and presentation choices, and the strategic responses to policy and trade developments that influence availability and cost profiles.

Against this backdrop, stakeholders are contending with a more complex risk matrix. Manufacturers are integrating next-generation platforms with legacy capacities, healthcare systems are revisiting immunization pathways to optimize uptake across diverse age cohorts, and procurement entities are balancing resilience against cost efficiency. The convergence of these forces creates both tension and opportunity: tension in supply continuity and procurement predictability, and opportunity in differentiated delivery solutions, targeted immunization strategies, and collaborative public-private interventions. Framing these dynamics up front clarifies why granular segmentation, regional nuance, and tariff-related shifts demand focused analysis and why strategic agility is now a competitive imperative.

This introductory perspective sets the stage for a deep-dive that combines technological, commercial, and policy lenses, ensuring that readers appreciate how near-term operational decisions map to longer-term strategic outcomes across the influenza vaccine ecosystem.

How platform diversification, delivery innovation, and supply chain modernization are reshaping market dynamics and stakeholder strategies in influenza immunization

The landscape for influenza vaccines is undergoing transformative shifts that extend beyond incremental product updates to encompass manufacturing architectures, delivery modalities, and stakeholder collaboration models. Platform diversification is a central axis of change: inactivated vaccine production continues to optimize throughput and yield, while live attenuated and recombinant approaches attract attention for their potential to deliver broader immune responses and faster production cycles. Concurrently, the industry is witnessing greater emphasis on delivery formats that enhance ease of administration and reduce wastage, including prefilled syringes with differentiated materials and vial formats engineered for flexible dosing strategies.

Beyond product innovation, systemic changes are reshaping stakeholder behavior. Payers and public health authorities are looking to align immunization schedules with demographic risk profiling, prompting a more granular focus on age-group specific strategies. At the same time, contract manufacturing and fill-finish specialization are accelerating, enabling smaller innovators and regional manufacturers to scale without extensive capital investment in upstream antigen production. Supply chain digitization and cold chain modernization are enabling tighter inventory control and real-time visibility, reducing stockouts and enabling more responsive distribution models.

These shifts are accompanied by evolving regulatory and public health frameworks that prioritize rapid response capacity and equitable access. The cumulative effect is a market environment that rewards adaptability, cross-sector partnerships, and investment in both platform versatility and delivery optimization. Stakeholders that anticipate these changes and align capability development with emerging policy expectations will be positioned to capture value and support resilient immunization programs.

Assessing the multifaceted consequences of United States tariff changes in 2025 on sourcing strategies, manufacturing localization, and supply chain resilience within the vaccine value chain

The cumulative impact of tariff adjustments introduced by the United States in 2025 has rippled through the influenza vaccine ecosystem, influencing sourcing decisions, input costs, and supply chain design. Producers that relied on cross-border procurement of specialized consumables, syringe components, and fill-finish materials encountered higher landed costs and longer procurement cycles. This dynamic prompted a series of tactical responses, including supplier diversification, renegotiation of long-term contracts, and localized sourcing for critical components to mitigate the volatility introduced by trade policy changes.

These tariff-driven pressures also accelerated conversations around regional manufacturing capacity and onshoring strategies. Facilities designed for fill-finish operations became more attractive as a means to reduce exposure to cross-border tariffs on finished goods, while partnerships between antigen producers and regional contract manufacturing organizations increased to minimize tariff leakage. At the same time, manufacturers are evaluating cost-to-serve tradeoffs across presentation formats; for some organizations, multi dose vials with shared distribution costs become more economically viable, while others prioritize prefilled syringe formats that reduce administration time and wastage, accepting higher component costs to secure market differentiation.

Beyond direct cost implications, the tariff environment has heightened regulatory and contractual scrutiny. Procurement teams are revisiting clauses related to force majeure, pricing pass-through, and supply continuity, while regulators are engaging with industry to ensure that trade measures do not unintentionally hinder public health preparedness. The aggregate effect is a more cautious procurement stance, with increased investment in supply chain visibility, scenario planning, and vendor risk assessment. Entities that proactively adjust their sourcing strategies and contractual frameworks are better equipped to preserve continuity of immunization programs amid trade-related headwinds.

Segment-driven strategic insights revealing how vaccine type, age cohort, dosing, presentation, distribution channel, and end-user characteristics interact to shape commercialization and delivery

Insights derived from segmentation analysis reveal differentiated opportunity spaces and operational priorities across vaccine type, age group, dosage, presentation, distribution channel, and end-user contexts. Based on vaccine type, distinctions between inactivated, live attenuated, and recombinant approaches matter for manufacturing lead times, cold chain sensitivity, and clinical guidance, which in turn influence procurement cadence and clinical training needs. Based on age group, adult, geriatric, and pediatric cohorts require tailored communication strategies, dosing considerations, and outreach models to optimize uptake and minimize adverse event concerns.

Based on dosage, the contrast between multi dose and single dose strategies affects inventory management, wastage rates, and per-dose administration logistics, while based on presentation, preferences for prefilled syringe and vial formats shape procurement of ancillary supplies and training of administering staff; the prefilled syringe pathway further differentiates into glass prefilled syringe and plastic prefilled syringe options with distinct shelf-life and handling implications, and the vial pathway divides into multi dose vial and single dose vial choices that carry different cold chain and multi-use governance considerations. Based on distribution channel, the roles of direct sales and hospital pharmacies influence lead times, contract structures, and visibility into end-user consumption. Based on end user, clinics and hospitals present divergent operational rhythms and procurement behaviors, with clinics further segmented into outpatient clinics and specialty clinics, and hospitals further segregated into private hospitals and public hospitals, each with unique purchasing cycles, reimbursement frameworks, and storage capacities.

These segmentation-driven insights underscore that strategic choices cannot be made in isolation: product platform decisions interact with presentation formats and end-user capabilities, and distribution channel strategies must align with age-group priorities and dosing strategies. Effective commercialization and public health planning therefore require cross-functional alignment between manufacturing, regulatory, procurement, and field operations, ensuring that product portfolios and delivery strategies map to the operational realities of the settings where vaccines are administered.

Regional strategic considerations and operational differentiators across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and deployment strategies

Regional dynamics materially influence how influenza vaccine strategies are developed and executed, with distinct operational, regulatory, and market-access considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, procurement models and public health programs emphasize national immunization campaigns supported by robust cold chain infrastructure in urban centers, while rural access and equitable distribution remain critical focus areas; private sector channels and direct-supply agreements shape commercial approaches in several key jurisdictions.

In Europe, Middle East & Africa, regulatory harmonization efforts and cross-border procurement mechanisms are important determinants of supply continuity and market entry strategies. Regulatory agencies in Europe prioritize stringent pharmacovigilance and batch-release oversight, while several markets within the broader EMEA region present opportunities for capacity building in cold chain and distribution. Growing attention to vaccine sovereignty in parts of the region has catalyzed partnerships aimed at enhancing local manufacturing and fill-finish capabilities.

Asia-Pacific exhibits a heterogeneous landscape where advanced manufacturing hubs coexist with emerging markets that have growing demand and variable cold chain maturity. The region features strong domestic producers in some countries and rapidly expanding public health programs in others, resulting in diverse procurement models and distribution challenges. Cross-border logistics, regional trade arrangements, and local regulatory pathways shape how manufacturers and distributors prioritize investments and partnerships in the region. Across all regions, alignment between product offerings, presentation choices, and the operational capacities of end-user settings is essential for effective immunization coverage and program sustainability.

Corporate strategies and partnership ecosystems that combine platform innovation, specialized manufacturing, and integrated delivery solutions to secure competitive advantage

Competitive dynamics among companies across the influenza vaccine ecosystem reflect a blend of platform incumbency, innovation partnerships, and specialization in ancillary components and delivery technologies. Established vaccine producers are balancing legacy inactivated platform efficiencies with investment in recombinant and novel antigen technologies that offer faster responsiveness and potential immunogenic advantages. At the same time, contract manufacturing organizations and specialty fill-finish providers are gaining strategic importance by enabling flexible scale-up and regionalized production models that reduce exposure to cross-border trade shifts.

Adjacencies with device manufacturers-particularly those that specialize in prefilled syringe materials and syringe component supply-play a pivotal role in differentiating product offerings. Companies that integrate device and vaccine solutions can present compelling value propositions to purchasers seeking reduced administration time and lower wastage. Strategic partnerships between developers, contract manufacturers, and logistics specialists are becoming more common, facilitating end-to-end solutions that cover antigen production, fill-finish, packaging, and last-mile cold chain capabilities.

Commercial and regulatory strategies are also evolving: some organizations prioritize long-term procurement contracts and collaborative risk-sharing arrangements with public health authorities, while others pursue flexible commercial models and targeted launches in markets with favorable regulatory pathways. Firms investing in digital supply chain platforms, enhanced batch traceability, and pharmacovigilance capabilities are better positioned to meet heightened regulatory scrutiny and procurement expectations. Overall, companies that combine platform innovation, supply chain agility, and collaborative commercial models will stand out in a landscape where both product efficacy and delivery efficiency determine competitive advantage.

Practical recommendations for strengthening supply resilience, optimizing presentation strategies, and aligning procurement and regulatory approaches to accelerate vaccine access

Industry leaders should prioritize actions that strengthen resilience, accelerate delivery innovation, and align commercial models with public health goals. First, invest in supplier diversification and localization initiatives that reduce exposure to single-source dependencies and trade-policy volatility; this includes strategic relationships with contract manufacturers and targeted investments in regional fill-finish capacity to shorten lead times and improve supply security. Second, rationalize presentation portfolios by balancing the operational advantages of prefilled syringes against the cost and logistical benefits of vial formats, making these choices in light of end-user capabilities, age-group needs, and wastage considerations.

Third, integrate digital supply chain and inventory management tools to enhance visibility and enable proactive redistribution during demand fluctuations; real-time data can inform rapid decisions on allocation and reduce stockouts. Fourth, design procurement and contracting frameworks that incorporate contingency clauses, demand-flexibility terms, and collaborative risk-sharing to safeguard continuity while maintaining cost discipline. Fifth, pursue cross-sector partnerships that align manufacturers, payers, and health systems around shared objectives such as increasing uptake in under-immunized groups and streamlining administration pathways.

Finally, prioritize regulatory and quality investments that shorten time to market for new platforms and presentations, including early engagement with regulatory authorities and reinforcement of pharmacovigilance systems. By taking these steps, industry leaders can transform uncertainty into strategic opportunity, ensuring that vaccine portfolios and distribution strategies are robust, adaptable, and aligned with evolving public health imperatives.

A robust mixed-methods research methodology combining secondary analysis, expert primary interviews, supply chain mapping, and scenario testing to inform actionable insights

This research synthesizes qualitative and quantitative methods to generate actionable insights that reflect both macro-level trends and operational realities. The approach begins with comprehensive secondary research across peer-reviewed literature, regulatory publications, and public health guidance to create a baseline understanding of platform technologies, presentation formats, and policy frameworks. Primary research complements this foundation through structured interviews with subject-matter experts including manufacturing leaders, supply chain executives, clinicians, and procurement specialists to capture experiential insights and on-the-ground constraints.

Supply chain mapping and scenario analysis are used to test the implications of tariff shifts, presentation choices, and regional distribution models, with sensitivity analyses that examine how changes in sourcing, lead times, and logistics capacity affect operational risk profiles. The research also incorporates case study analysis of recent program rollouts and technology transitions to identify practical lessons in rollout planning, training, and wastage management. Quality assurance measures include cross-validation of primary interview findings with regulatory filings and publicly available procurement documentation, ensuring that conclusions are triangulated across multiple evidence streams.

Throughout the methodology, emphasis is placed on transparency and reproducibility: data sources and analytical assumptions are documented, and methodological limitations are acknowledged to guide interpretation. This mixed-methods approach ensures that strategic recommendations are grounded in both empirical evidence and practitioner expertise, making them relevant for decision-makers seeking implementable solutions.

A concluding synthesis emphasizing the imperative for integrated, segmentation-aware strategies across innovation, procurement, and distribution to ensure enduring vaccine access

In conclusion, the influenza vaccine ecosystem is at an inflection point where platform innovation, presentation choices, and supply chain resilience collectively determine program success. Stakeholders must navigate a complex set of tradeoffs: balancing the benefits of advanced recombinant or live attenuated technologies with the pragmatic realities of manufacturing capacity and distribution readiness, and reconciling the administrative efficiencies of prefilled syringe solutions with the cost and wastage dynamics of vial-based approaches. Tariff-related policy shifts have underscored the importance of sourcing diversification and regional manufacturing strategies, reinforcing the need for contractual and operational agility.

Effective responses require holistic strategies that span product development, procurement, and field implementation. By aligning segmentation-aware product strategies with regional operational capabilities, and by investing in digital visibility and collaborative commercial models, organizations can reduce risk and enhance access. The most successful actors will be those that treat the vaccine lifecycle as a system problem-one that demands integrated solutions across manufacturing, logistics, regulatory engagement, and end-user support. This systemic lens will be essential for translating technological advances into sustainable immunization outcomes and for ensuring that influenza vaccination programs meet public health objectives efficiently and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Vaccine Market, by Vaccine Type

  • 8.1. Inactivated
  • 8.2. Live Attenuated
  • 8.3. Recombinant

9. Influenza Vaccine Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Influenza Vaccine Market, by Dosage

  • 10.1. Multi Dose
  • 10.2. Single Dose

11. Influenza Vaccine Market, by Presentation

  • 11.1. Prefilled Syringe
    • 11.1.1. Glass Prefilled Syringe
    • 11.1.2. Plastic Prefilled Syringe
  • 11.2. Vial
    • 11.2.1. Multi Dose Vial
    • 11.2.2. Single Dose Vial

12. Influenza Vaccine Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies

13. Influenza Vaccine Market, by End User

  • 13.1. Clinics
    • 13.1.1. Outpatient Clinics
    • 13.1.2. Specialty Clinics
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals

14. Influenza Vaccine Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Influenza Vaccine Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Influenza Vaccine Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Influenza Vaccine Market

18. China Influenza Vaccine Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AstraZeneca plc
  • 19.6. Changchun BCH Bioengineering Co., Ltd.
  • 19.7. China National Pharmaceutical Group Co., Ltd.
  • 19.8. CSL Limited
  • 19.9. GlaxoSmithKline plc
  • 19.10. Pfizer Inc.
  • 19.11. Sanofi S.A.
  • 19.12. Serum Institute of India Private Limited
  • 19.13. Sinovac Biotech Ltd.
  • 19.14. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GCC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. G7 INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. NATO INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. NATO INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)